Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Veneto-STOP: MRD detection by NGS to optimize treatment outcomes with venetoclax

Chaitra Ujjani • 7 Dec 2019
ASH 2019
Chronic Lymphocytic Leukemia Leukemia Venetoclax

Undetectable measurable residual disease (uMRD) with venetoclax therapy is associated with improved PFS in patients with chronic lymphocytic leukemia (CLL). Chaitra Ujjani, MD, University of Washington & Fred Hutchinson Cancer Research Center, Seattle, WA, explains the rationale of utilizing MRD assessment with a next generation sequencing (NGS) assay in order to guide clinical decision making in patients with CLL that are receiving venetoclax-based regimens. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Chaitra Ujjani

0:49
Extending survival in patients with CLL: novel agents, MRD, and overcoming RT
Chaitra Ujjani • 11 Dec 2023
1:13
Dual-targeted regimens for the treatment of CLL: anti-CD20 antibodies, BTKi, and BCL2i
Chaitra Ujjani • 11 Dec 2023
2:09
Incidence of COVID-19 infections in vaccinated patients with CLL
Chaitra Ujjani • 11 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals